Bionovate Technologies Corp
BIIO · OTC
9/30/2021 | 6/30/2021 | 3/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | -0.00 | -0.00 |
| FCF Yield | 0.00% | 0.00% | 14.23% | -26.08% |
| EV / EBITDA | -37.83 | -54.26 | -13.91 | -9.76 |
| Quality | ||||
| ROIC | 2.19% | 1.65% | 6.61% | 8.24% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | – | – | -0.00 | 0.01 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | -100.00% | 116.31% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -37.83 | -54.25 | -13.89 | -9.71 |
| Interest Coverage | -0.41 | -0.29 | -1.11 | -1.80 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |